{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:51:55Z","timestamp":1786985515085,"version":"build-2736575974"},"reference-count":65,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biosafety and Health"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bsheal.2024.09.001","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T13:02:53Z","timestamp":1725368573000},"page":"270-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Drupacine as a potent SARS-CoV-2 replication inhibitor in vitro"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1763-5404","authenticated-orcid":false,"given":"Chen","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bsheal.2024.09.001_b0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bsheal.2024.09.001_b0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bsheal.2024.09.001_b0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.bsheal.2024.09.001_b0020","doi-asserted-by":"crossref","unstructured":"S. Gandhi, J. Klein, A.J. Robertson, M.A. Pe\u00f1a-Hern\u00e1ndez, M.J. Lin, P. Roychoudhury, P. Lu, J. Fournier, D. Ferguson, S.A.K. Mohamed Bakhash, et al., De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report, Nat. Commun. 13 (2022) 1547, https:\/\/doi.org\/10.1038\/s41467-022-29104-y.","DOI":"10.1038\/s41467-022-29104-y"},{"key":"10.1016\/j.bsheal.2024.09.001_b0025","doi-asserted-by":"crossref","unstructured":"A. Heyer, T. G\u00fcnther, A. Robitaille, M. L\u00fctgehetmann, M.M. Addo, D. Jarczak, S. Kluge, M. Aepfelbacher, J. Schulze Zur Wiesch, N. Fischer, A. Grundhoff, et al., Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection, Cell Rep. Med. 3 (2022) 100735, https:\/\/doi.org\/10.1016\/j.xcrm.2022.100735.","DOI":"10.1016\/j.xcrm.2022.100735"},{"key":"10.1016\/j.bsheal.2024.09.001_b0030","doi-asserted-by":"crossref","unstructured":"J.T. Lee, Q. Yang, A. Gribenko, B.S. Perrin, Y. Zhu, R. Cardin, P.A. Liberator, A.S. Anderson, L. Hao, Genetic surveillance of SARS-CoV-2 Mpro reveals high sequence and structural conservation prior to the introduction of protease inhibitor paxlovid, mBio 13 (2022) e00869-22. https:\/\/doi.org\/10.1128\/mbio.00869-22.","DOI":"10.1128\/mbio.00869-22"},{"key":"10.1016\/j.bsheal.2024.09.001_b0035","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.bsheal.2024.09.001_b0040","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jama.2022.13854","article-title":"Development of resistance-associated mutations after sotrovimab administration in high-risk individuals infected with the SARS-CoV-2 omicron variant","volume":"328","author":"Birnie","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.bsheal.2024.09.001_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104559","article-title":"K. W. To, Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance","volume":"91","author":"Ip","year":"2023","journal-title":"eBioMedicine"},{"key":"10.1016\/j.bsheal.2024.09.001_b0050","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir","volume":"9","author":"Hu","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bsheal.2024.09.001_b0055","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.hlife.2024.06.003","article-title":"Why is the omicron main protease of SARS-CoV-2 less stable than its wild-type counterpart? A crystallographic, biophysical, and theoretical study","volume":"2","author":"Ibrahim","year":"2024","journal-title":"hLife"},{"key":"10.1016\/j.bsheal.2024.09.001_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107930","article-title":"Drug repurposing for COVID-19: Approaches, challenges and promising candidates","volume":"228","author":"Ng","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bsheal.2024.09.001_b0065","article-title":"The journey of remdesivir: From Ebola to COVID-19, Drugs","volume":"9","author":"Pardo","year":"2020","journal-title":"Context"},{"key":"10.1016\/j.bsheal.2024.09.001_b0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coviro.2021.06.003","article-title":"Developing a direct acting, orally available antiviral agent in a pandemic: The evolution of molnupiravir as a potential treatment for COVID-19","volume":"50","author":"Painter","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.bsheal.2024.09.001_b0075","doi-asserted-by":"crossref","first-page":"e02428","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bsheal.2024.09.001_b0080","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses \u2014 drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bsheal.2024.09.001_b0085","doi-asserted-by":"crossref","first-page":"9241","DOI":"10.1073\/pnas.2004999117","article-title":"Phylogenetic network analysis of SARS-CoV-2 genomes","volume":"117","author":"Forster","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.bsheal.2024.09.001_b0090","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bsheal.2024.09.001_b0095","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bsheal.2024.09.001_b0100","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.bsheal.2024.09.001_b0105","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1126\/science.abf7945","article-title":"X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease","volume":"372","author":"G\u00fcnther","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bsheal.2024.09.001_b0110","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2012201118","article-title":"Bepridil is potent against SARS-CoV-2 in vitro","volume":"118","author":"Vatansever","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bsheal.2024.09.001_b0115","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1021\/acscentsci.1c00519","article-title":"Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay","volume":"7","author":"Ma","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bsheal.2024.09.001_b0120","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","article-title":"Progress and challenges in targeting the SARS-CoV-2 papain-like protease","volume":"65","author":"Tan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bsheal.2024.09.001_b0125","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1007\/s13238-022-00909-3","article-title":"Targeting papain-like protease for broad-spectrum coronavirus inhibition","volume":"13","author":"Yuan","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.bsheal.2024.09.001_b0130","first-page":"17","article-title":"High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors","volume":"14","author":"Zang","year":"2023","journal-title":"Protein Cell"},{"key":"10.1016\/j.bsheal.2024.09.001_b0135","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1126\/science.adm9724","article-title":"Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model","volume":"383","author":"Tan","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.bsheal.2024.09.001_b0140","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cell.2020.06.034","article-title":"The global phosphorylation landscape of SARS-CoV-2 infection","volume":"182","author":"Bouhaddou","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bsheal.2024.09.001_b0145","doi-asserted-by":"crossref","unstructured":"R. Wang, C.R. Simoneau, J. Kulsuptrakul, M. Bouhaddou, K.A. Travisano, J.M. Hayashi, J. Carlson-Stevermer, J.R. Zengel, C.M. Richards, P. Fozouni, et al., Genetic screens identify host factors for SARS-CoV-2 and common cold coronaviruses, Cell 184 (2021) 106\u2013119 e14, https:\/\/doi.org\/10.1016\/j.cell.2020.12.004.","DOI":"10.1016\/j.cell.2020.12.004"},{"key":"10.1016\/j.bsheal.2024.09.001_b0150","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s42256-020-00285-9","article-title":"A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing","volume":"3","author":"Pham","year":"2021","journal-title":"Nat. Mach. Intell."},{"key":"10.1016\/j.bsheal.2024.09.001_b0155","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","article-title":"Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing","volume":"586","author":"Riva","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bsheal.2024.09.001_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009439","article-title":"A novel cell culture system modeling the SARS-CoV-2 life cycle","volume":"17","author":"Ju","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bsheal.2024.09.001_b0165","first-page":"e4257","article-title":"A nucleocapsid-based transcomplementation cell culture system of SARS-CoV-2 to recapitulate the complete viral life cycle","volume":"11","author":"Yu","year":"2021","journal-title":"Bio Protoc."},{"key":"10.1016\/j.bsheal.2024.09.001_b0170","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"SLAS Discov."},{"key":"10.1016\/j.bsheal.2024.09.001_b0175","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.virs.2022.02.009","article-title":"Efficient assembly of a large fragment of monkeypox virus genome as a qPCR template using dual-selection based transformation-associated recombination","volume":"37","author":"Yang","year":"2022","journal-title":"Virol. Sin."},{"key":"10.1016\/j.bsheal.2024.09.001_b0180","doi-asserted-by":"crossref","first-page":"107774","DOI":"10.1016\/j.celrep.2020.107774","article-title":"Structural and biochemical characterization of the nsp12-nsp7-nsp8 core polymerase complex from SARS-CoV-2","volume":"31","author":"Peng","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.bsheal.2024.09.001_b0185","doi-asserted-by":"crossref","first-page":"105764","DOI":"10.1016\/j.antiviral.2023.105764","article-title":"High content screening strategies for large-scale compound libraries with a focus on high-containment viruses","volume":"221","author":"Subramani","year":"2024","journal-title":"Antiviral Res."},{"issue":"2020","key":"10.1016\/j.bsheal.2024.09.001_b0190","first-page":"1051","article-title":"Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model","volume":"133","author":"Fan","year":"2019","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.bsheal.2024.09.001_b0195","doi-asserted-by":"crossref","first-page":"102367","DOI":"10.1016\/j.isci.2021.102367","article-title":"Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment","volume":"24","author":"Ohashi","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.bsheal.2024.09.001_b0200","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1126\/science.abg5827","article-title":"Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2","volume":"373","author":"Drayman","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bsheal.2024.09.001_b0205","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.hlife.2023.12.001","article-title":"Lycorine derivative effectively inhibits the replication of coronaviruses both in vitro and in vivo","volume":"2","author":"Shen","year":"2024","journal-title":"hLife"},{"key":"10.1016\/j.bsheal.2024.09.001_b0210","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ps.3548","article-title":"Nematotoxicity of drupacine and a Cephalotaxus alkaloid preparation against the plant-parasitic nematodes Meloidogyne incognita and Bursaphelenchus xylophilus","volume":"69","author":"Wen","year":"2013","journal-title":"Pest Manag. Sci."},{"key":"10.1016\/j.bsheal.2024.09.001_b0215","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bsheal.2024.09.001_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104974","article-title":"A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2","volume":"185","author":"Zhang","year":"2021","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bsheal.2024.09.001_b0225","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1038\/s41467-020-18096-2","article-title":"Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"11","author":"Vuong","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bsheal.2024.09.001_b0230","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bsheal.2024.09.001_b0235","doi-asserted-by":"crossref","first-page":"E3900","DOI":"10.1073\/pnas.1323705111","article-title":"One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities","volume":"111","author":"Subissi","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bsheal.2024.09.001_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.xinn.2021.100080","article-title":"Structural basis of SARS-CoV-2 polymerase inhibition by favipiravir","volume":"2","author":"Peng","year":"2021","journal-title":"The Innovation"},{"key":"10.1016\/j.bsheal.2024.09.001_b0245","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00162-20","article-title":"Remdesivir against COVID-19 and other viral diseases","volume":"34","author":"Malin","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.bsheal.2024.09.001_b0250","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1016\/j.cell.2022.09.037","article-title":"A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analog inhibitors","volume":"185","author":"Yan","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.bsheal.2024.09.001_b0255","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.1093\/nar\/gkz409","article-title":"Delicate structural coordination of the severe acute respiratory syndrome coronavirus Nsp13 upon ATP hydrolysis","volume":"47","author":"Jia","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bsheal.2024.09.001_b0260","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJM199508173330710","article-title":"Time to hit HIV, early and hard","volume":"333","author":"Ho","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bsheal.2024.09.001_b0265","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2016.11.017","article-title":"Synergistic drug combination effectively blocks Ebola virus infection","volume":"137","author":"Sun","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bsheal.2024.09.001_b0270","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ymthe.2020.12.016","article-title":"Synergistic and antagonistic drug combinations against SARS-CoV-2","volume":"29","author":"Bobrowski","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bsheal.2024.09.001_b0275","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.drudis.2021.05.008","article-title":"Drug combination therapy for emerging viral diseases","volume":"26","author":"Shyr","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bsheal.2024.09.001_b0280","doi-asserted-by":"crossref","first-page":"40318","DOI":"10.18632\/oncotarget.16956","article-title":"Homoharringtonine targets Smad3 and TGF-\u03b2 pathway to inhibit the proliferation of acute myeloid leukemia cells","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bsheal.2024.09.001_b0285","doi-asserted-by":"crossref","first-page":"12940","DOI":"10.1080\/21655979.2021.2012626","article-title":"Uncovering the action mechanism of homoharringtonine against colorectal cancer by using network pharmacology and experimental evaluation","volume":"12","author":"Qu","year":"2021","journal-title":"Bioengineered"},{"key":"10.1016\/j.bsheal.2024.09.001_b0290","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/v10110601","article-title":"The natural compound homoharringtonine presents broad antiviral activity in vitro and in vivo","volume":"10","author":"Dong","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.bsheal.2024.09.001_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bsheal.2024.09.001_b0300","doi-asserted-by":"crossref","first-page":"100849","DOI":"10.1016\/j.eclinm.2021.100849","article-title":"Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with COVID-19-a double-blind randomized controlled trial","volume":"35","author":"Gunst","year":"2021","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.bsheal.2024.09.001_b0305","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ijid.2022.06.054","article-title":"Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial","volume":"122","author":"Tobback","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.bsheal.2024.09.001_b0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-019-0132-8","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.bsheal.2024.09.001_b0315","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41586-020-2575-3","article-title":"Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2","volume":"585","author":"Hoffmann","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bsheal.2024.09.001_b0320","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa2016638","article-title":"A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19","volume":"383","author":"Boulware","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bsheal.2024.09.001_b0325","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamainternmed.2020.6319","article-title":"Prevention and Treatment of COVID-19 With Hydroxychloroquine (PATCH) Investigators, Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial","volume":"181","author":"Abella","year":"2021","journal-title":"JAMA Intern. Med."}],"container-title":["Biosafety and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590053624001071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590053624001071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T17:37:23Z","timestamp":1731519443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590053624001071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2590053624001071"],"URL":"https:\/\/doi.org\/10.1016\/j.bsheal.2024.09.001","relation":{},"ISSN":["2590-0536"],"issn-type":[{"value":"2590-0536","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drupacine as a potent SARS-CoV-2 replication inhibitor in vitro","name":"articletitle","label":"Article Title"},{"value":"Biosafety and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bsheal.2024.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Chinese Medical Association Publishing House. Published by Elsevier BV.","name":"copyright","label":"Copyright"}]}}